Paper9102399
Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3).
Degerman E and 2 others. J Biol Chem, 1997. Cited by 363 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). Papers, record 9102399. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9102399
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| 3',5'-Cyclic-AMP Phosphodiesterases | Major topic |
| Animals | |
| Cyclic Nucleotide Phosphodiesterases, Type 3 | |
| Gene Expression Regulation, Enzymologic | |
| Humans |
Source PubMed
Cited by111
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 363 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,236,056 | Intercellular cyclic nucleotide dynamics mediate oocyte meiosis in mammalian preovulatory follicles. | Curr Top Dev Biol | 2026 | https://conductscience.org/library/papers/42236056 | PubMed |
| 42,047,795 | Pan-cancer ex vivo target evaluation of phosphodiesterase 3 A (PDE3A). | J Mol Med (Berl) | 2026 | https://conductscience.org/library/papers/42047795 | PubMed |
| 41,757,835 | In vitro maturation 2.0: a new era for an underdog in ART. | JBRA Assist Reprod | 2026 | https://conductscience.org/library/papers/41757835 | PubMed |
| 41,732,176 | Phosphodiesterase inhibitors as emerging therapeutics for skeletal disorders: A comprehensive review of mechanisms and repurposing potential. | Bone Rep | 2026 | https://conductscience.org/library/papers/41732176 | PubMed |
| 41,227,315 | Cyclic Nucleotide Phosphodiesterase Families as Targets to Treat Pulmonary Arterial Hypertension: Beyond PDE5 Inhibitors? | Cells | 2025 | https://conductscience.org/library/papers/41227315 | PubMed |
| 41,150,877 | Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/41150877 | PubMed |
| 40,100,370 | Cilostazol alleviates imatinib-induced myocardial injury in rats by modulating the TGF-β1/MAPK, SHC/Grb2/SOS signaling pathways and upregulating miRNA-195-5P. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40100370 | PubMed |
| 39,572,771 | Integrated responses of the SIP syncytium generate a major motility pattern in the colon. | J Physiol | 2024 | https://conductscience.org/library/papers/39572771 | PubMed |
| 39,435,735 | Pde3a and Pde3b regulation of murine pulmonary artery smooth muscle cell growth and metabolism. | Physiol Rep | 2024 | https://conductscience.org/library/papers/39435735 | PubMed |
| 39,273,390 | Cyclic Adenosine Monophosphate Signaling in Chronic Kidney Disease: Molecular Targets and Therapeutic Potentials. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39273390 | PubMed |
| 38,473,840 | The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38473840 | PubMed |
| 38,262,506 | The perspective of cAMP/cGMP signaling and cyclic nucleotide phosphodiesterases in aortic aneurysm and dissection. | Vascul Pharmacol | 2024 | https://conductscience.org/library/papers/38262506 | PubMed |
| 37,781,231 | A preliminary study of phosphodiesterases and adenylyl cyclase signaling pathway on red blood cell deformability of sickle cell patients. | Front Physiol | 2023 | https://conductscience.org/library/papers/37781231 | PubMed |
| 37,540,009 | Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans. | Brain | 2023 | https://conductscience.org/library/papers/37540009 | PubMed |
| 37,324,679 | A cAMP phosphodiesterase is essential for sclerotia formation and virulence in Sclerotinia sclerotiorum. | Front Plant Sci | 2023 | https://conductscience.org/library/papers/37324679 | PubMed |
| 37,165,086 | It takes two to tango: cardiac fibroblast-derived NO-induced cGMP enters cardiac myocytes and increases cAMP by inhibiting PDE3. | Commun Biol | 2023 | https://conductscience.org/library/papers/37165086 | PubMed |
| 36,817,146 | Sildenafil affects the human Kir2.1 and Kir2.2 channels at clinically relevant concentrations: Inhibition potentiated by low Ba2. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/36817146 | PubMed |
| 36,813,290 | Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. | Eur Respir Rev | 2023 | https://conductscience.org/library/papers/36813290 | PubMed |
| 36,268,188 | Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease. | Front Aging Neurosci | 2022 | https://conductscience.org/library/papers/36268188 | PubMed |
| 36,015,172 | Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/36015172 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9102399
GET https://conductscience.org/api/papers/v1/9102399/cited_by?page=2